Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 213-223

  Poon, Kitty ^a   King, Allen B ^a  

^a Diabetes Care Center   (United States)

Author keywords

Detemir; Glargine; Glucose variability; Hypoglycemia; Safety; Weight

Indexed keywords

DRUG PRESERVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN RECEPTOR; ISOPHANE INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; ZINC;

ADD ON THERAPY; ADULT; AGE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING COMPETITION; BODY MASS; CANCER RISK; CAPILLARY FLOW; CAPILLARY PERMEABILITY; CHEMICAL MODIFICATION; CHILD; DIABETIC MICROANGIOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ETHNIC GROUP; FLOW RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; INTERSTITIAL FLUID; LIPOGENESIS; MEAL; MITOGENICITY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PH; PHARMACODYNAMICS; PLACENTAL TRANSFER; PREGNANCY; PREMEAL; RECEPTOR AFFINITY; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS TISSUE; WEIGHT GAIN;

EID: 78650700079     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S7301     Document Type: Review

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and 2030. Diabetes Care. 2004;27:1047-1053.
2. World Health Organization. WHO Global Strategy on Diet, Physical Activity, and Health: Diabetes. Available from: http://www.who.int/dietphysicalactivity/publications/facts/diabetes/en/. Accessed 2010 Feb 28.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetes microvascular complications in Japanese patients with NIDDM: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
8. American Diabetes Association. Standards of medical care in diabetes-2010 (Position Statement). Diabetes Care. 2010;33 Suppl 1: S11-S61.
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
10. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
11. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
12. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
13. sanofi-aventis. Lantus [package insert] Paris, France: sanofi-aventis; 2007.
14. Norvo Nordisk Inc. Detemir [package insert]. Princeton, NJ: Novo Nordisk; 2005.
15. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab. 2005;31:4S25-4S33.
16. Heinnemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
17. Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125Ilabeled insulin glargine (HOE 901) in healthy men. Diabetes Care. 2000;23:813-819.
18. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. Int J Obes. 2004;28:S23-S28.
19. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting acylated analog of human insulin. Pharm Res. 2004;21:1498-1504.
20. Dea MK, Hamilton-Wessler M, Ader M, et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes. 2002;51:762-769.
21. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamps studies. Diabetes Obes Metab. 2007;9:648-659.
22. HOE 901/1015 Study Investigators Group. Comparison of the timeaction profiles of HOE 901 and human NPH insulin in type 1 diabetic patients using the euglycemic clamp technique. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21981_Lantus_biopharmr.pdf. Accessed 2010 Sep 08.
23. Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447-2452.
24. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112.
25. Klein O, Lynge J, Endahl L, Damolt B, Nosek L, Heise T. Albuminbound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-299.
26. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613.
27. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635-642.
28. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51:408-416.
29. Hollander P, Cooper J, Bregnhoj J, Pederson CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987.
30. King AB. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: A cross-over, double-blind, and randomized study using continuous glucose monitoring. J Diabetes Sci Technol. 2010;4:151-154.
31. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14 week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61:523-528.
32. Dornhorst A, Luddeke HJ, Koenen C, et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral anitdiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab. 2008;10:75-81.
33. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418-427.
34. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: Results from a subgroup of the PREDICTIVE study. Int J Clin Pract. 2009;63:425-432.
35. Cryer P, editor. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA: American Diabetes Association; 2009.
36. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
37. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.
38. Hemkins LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia. 2009;52:1732-1744.
39. Ehninger G, Schmidt AH. Putting insulin glargine and malignancies into perspective. Oncologist. 2009;14:1169-1174.
40. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. Diabetes Care. 2010;33:1674-1685.
41. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: A transplacental transfer study. Diabetes Care. 2010;33:29-33.
42. Danne T, Lupke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003;26:3087-3092.
43. Hompesch M, Troupin B, Heise T, et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006;8:568-573.
44. Hollander P. Anti-diabetes and anti-obesity medications: Effects on weight in people with diabetes. Diabetes Spectr. 2007;20:159-165.
45. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9:209-217.
46. Hennige AM, Sartorius T, Tschritter O, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia. 2006;49:1274-1282.